FloDesign Sonics, a Wilbraham, MA-based life science company, closed a Series A2 funding of undisclosed amount.
The round was led by Dynamk Capital with participation from a group of life science leaders and former executives with proven track records.
The company intends to use the funds to advance the commercial production of CAR T and immunotherapies.
Founded in 2010 by Stanley Kowalski, CEO, FloDesign Sonics develops acoustic technologies for the separation, concentration and purification of materials in an active fluid. Their key focus area is cell therapy, helping to address manufacturing challenges related to the processing, separation and purification of CAR T cells.